The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...
The FINANCIAL — Boehringer Ingelheim on July 11 announced final results from RE-VERSE AD. The study shows that Praxbind (idarucizumab) was able to immediately and completely reverse the anticoagulant ...
Praxbind, a humanized monoclonal antibody fragment, is available as 2.5g/50mL strength solution for intravenous (IV) infusion in single-use vials. For more information call (800) 542-6257 or visit ...
RIDGEFIELD, Conn., May 4, 2018 /PRNewswire/ -- Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate mesylate), is now ...
iv anticoagulant Boehringer Ingelheim has announced that Praxbind, a reversal agent for the oral anticoagulant Pradaxa (dabigatran etexilate mesylate), is now available in over 2,200 hospitals across ...
The FDA has approved Boehringer’s Praxbind for use when the reversal of anticoagulant Pradaxa is required in emergency situations. The safety and efficacy of Praxbind (idarucizumab) was studied in ...
INGELHEIM, Germany., The European Commission has approved Praxbind ® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa ® (dabigatran etexilate) in ...
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa ® (dabigatran etexilate)
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim GmbH announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind ® (idarucizumab). 4 Praxbind ® is indicated for ...
Please provide your email address to receive an email when new articles are posted on . The FDA today granted accelerated approval to idarucizumab, which is intended for patients who require emergency ...
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results